| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-2522-2 |
| P698 | PubMed publication ID | 14729627 |
| P50 | author | Barbara Seliger | Q88457780 |
| Gerd Sutter | Q38804711 | ||
| Jan G Hengstler | Q49800573 | ||
| Ingo Drexler | Q64258344 | ||
| P2093 | author name string | Hans-Anton Lehr | |
| Felix Herrmann | |||
| Ursula Wollscheid | |||
| P2860 | cites work | Tight control of gene expression in mammalian cells by tetracycline-responsive promoters | Q24564850 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 215-220 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway | |
| P478 | volume | 64 |
| Q98625902 | A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation |
| Q36522859 | An evolutionary perspective on anti-tumor immunity |
| Q34105959 | Anti-HER2 vaccines: new prospects for breast cancer therapy |
| Q52597557 | Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. |
| Q36653524 | Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade |
| Q36015421 | CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers |
| Q37882478 | Camouflage and sabotage: tumor escape from the immune system |
| Q36605526 | Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies? |
| Q36083431 | Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions |
| Q37132708 | EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects |
| Q36836135 | Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling |
| Q36143622 | Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer |
| Q36487452 | Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells |
| Q33816300 | Equine major histocompatibility complex class I molecules act as entry receptors that bind to equine herpesvirus-1 glycoprotein D |
| Q36388523 | Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression |
| Q36002622 | Expression of antigen processing and presenting molecules in brain metastasis of breast cancer |
| Q30318099 | HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties |
| Q64985026 | HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. |
| Q30318613 | Identification of E2F1 as an important transcription factor for the regulation of tapasin expression |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q54478329 | Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model. |
| Q28538654 | Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study |
| Q35154283 | Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models |
| Q40181511 | Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q39680556 | Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma |
| Q91671471 | KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC |
| Q47306639 | Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. |
| Q41909644 | Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model |
| Q26866479 | MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells |
| Q39396738 | Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation |
| Q30318252 | Novel insights into the molecular mechanisms of HLA class I abnormalities |
| Q39139069 | Oncogenic growth factor signaling mediating tumor escape from cellular immunity |
| Q36388560 | Opposing consequences of signaling through EGF family members: Escape from CTLs could be a bait for NK cells |
| Q90238955 | Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression |
| Q26861053 | Plant sterols as anticancer nutrients: evidence for their role in breast cancer |
| Q47704805 | Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. |
| Q46789413 | Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer |
| Q35920773 | STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients |
| Q47350013 | Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer |
| Q36429691 | Targeting the ubiquitin-proteasome pathway in breast cancer therapy |
| Q37377808 | The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer |
| Q57114285 | The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer |
| Q28546094 | The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells |
| Q34208784 | The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells |
| Q36350565 | Towards a therapeutic breast cancer vaccine: the next steps |
| Q36821168 | Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. |
| Q27009908 | Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity |
| Q27691330 | Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model |
| Q37414561 | Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide |
| Q33991804 | Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial |
| Q35786634 | Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer |
| Q35533034 | XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine |
Search more.